[go: up one dir, main page]

NL301081I1 - - Google Patents

Info

Publication number
NL301081I1
NL301081I1 NL301081C NL301081C NL301081I1 NL 301081 I1 NL301081 I1 NL 301081I1 NL 301081 C NL301081 C NL 301081C NL 301081 C NL301081 C NL 301081C NL 301081 I1 NL301081 I1 NL 301081I1
Authority
NL
Netherlands
Application number
NL301081C
Other versions
NL301081I2 (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47221305&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301081(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NL301081I1 publication Critical patent/NL301081I1/nl
Publication of NL301081I2 publication Critical patent/NL301081I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
NL301081C 2011-11-28 2020-12-18 Avelumab NL301081I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563903P 2011-11-28 2011-11-28
PCT/EP2012/004822 WO2013079174A1 (en) 2011-11-28 2012-11-21 Anti-pd-l1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
NL301081I1 true NL301081I1 (nl) 2020-12-23
NL301081I2 NL301081I2 (nl) 2021-02-04

Family

ID=47221305

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301081C NL301081I2 (nl) 2011-11-28 2020-12-18 Avelumab

Country Status (28)

Country Link
US (4) US9624298B2 (nl)
EP (2) EP3763741A1 (nl)
JP (2) JP6138813B2 (nl)
KR (2) KR101764096B1 (nl)
CN (1) CN103987405B (nl)
AR (1) AR089010A1 (nl)
AU (2) AU2012344260B2 (nl)
BR (1) BR112014012819B1 (nl)
CA (1) CA2856895C (nl)
CY (2) CY1123435T1 (nl)
DK (1) DK2785375T3 (nl)
EA (1) EA036814B9 (nl)
ES (1) ES2808152T3 (nl)
FR (1) FR20C1068I2 (nl)
HR (1) HRP20201595T1 (nl)
HU (2) HUE051954T2 (nl)
IL (2) IL232778B (nl)
LT (2) LT2785375T (nl)
MX (1) MX349096B (nl)
NL (1) NL301081I2 (nl)
NO (1) NO2021003I1 (nl)
PT (1) PT2785375T (nl)
RS (1) RS61033B1 (nl)
SG (1) SG11201402603WA (nl)
SI (1) SI2785375T1 (nl)
SM (1) SMT202000561T1 (nl)
WO (1) WO2013079174A1 (nl)
ZA (1) ZA201404790B (nl)

Families Citing this family (1007)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104356236B (zh) * 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP4331604B9 (en) 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
EP2625292B1 (en) 2010-10-07 2018-12-05 The General Hospital Corporation Biomarkers of cancer
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
ES2808152T3 (es) 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
MX363872B (es) * 2012-05-31 2019-04-05 Genentech Inc Anticuerpos anti-pd-l1 y antagonistas de vegf y su uso en el tratamiento del cáncer.
MX2015007051A (es) 2012-12-07 2016-01-12 Chemocentryx Inc Diazol lactamas.
EP3640375A3 (en) * 2012-12-11 2020-07-29 Albert Einstein College of Medicine Methods for high throughput receptor/ligand identification
ES2721168T3 (es) 2013-01-11 2019-07-29 Dingfu Biotarget Co Ltd Agentes para tratar tumores, uso y método de los mismos
AU2014235453A1 (en) 2013-03-15 2015-10-08 Genentech, Inc. Biomarkers and methods of treating PD-1 and PD-L1 related conditions
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AU2014276440A1 (en) 2013-06-03 2015-11-05 Novartis Ag Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor
IL292193B2 (en) 2013-09-11 2024-11-01 Medimmune Ltd Anti-b7-h1 antibodies for treating tumors
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
SG11201602283UA (en) 2013-09-27 2016-04-28 Genentech Inc Anti-pdl1 antibody formulations
US10202454B2 (en) * 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
KR20240017102A (ko) 2013-12-17 2024-02-06 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
CA2934953C (en) 2013-12-24 2022-09-20 Bristol-Myers Squibb Company Substituted pyrido[3,2-b]indoyl compounds and pharmaceutical compositions thereof as anticancer agents
AU2015206603B9 (en) * 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
US10407502B2 (en) * 2014-01-15 2019-09-10 Kadmon Corporation, Llc Immunomodulatory agents
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
HUE054873T2 (hu) * 2014-02-10 2021-10-28 Merck Patent Gmbh Célzott TGF-béta-gátlás
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
JP6153674B2 (ja) 2014-03-24 2017-06-28 ノバルティス アーゲー 細菌感染を治療するためのモノバクタム有機化合物
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
RU2695332C2 (ru) 2014-05-15 2019-07-23 Бристол-Маерс Сквибб Компани Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства
EP3149042B1 (en) 2014-05-29 2019-08-28 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
RU2016149812A (ru) 2014-06-06 2018-07-17 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
WO2015200697A1 (en) 2014-06-25 2015-12-30 The General Hospital Corporation Targeting human satellite ii (hsatii)
CN110156892B (zh) * 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
JP6760919B2 (ja) 2014-07-09 2020-09-23 バーディー バイオファーマシューティカルズ インコーポレイテッド 腫瘍を治療するための抗ｐｄ−ｌ１組み合わせ
WO2016007876A1 (en) * 2014-07-10 2016-01-14 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
RU2715038C2 (ru) 2014-07-11 2020-02-21 Дженентек, Инк. Антитела анти-pd-l1 и способы их диагностического применения
SG10201900571YA (en) 2014-07-22 2019-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
EP3936145A1 (en) * 2014-07-31 2022-01-12 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
EP3177593A1 (en) 2014-08-06 2017-06-14 Novartis AG Quinolone derivatives as antibacterials
US20170239351A1 (en) 2014-08-11 2017-08-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
LT3180363T (lt) 2014-08-15 2019-11-25 Merck Patent Gmbh Sirp-alfa imunoglobulino sulieti baltymai
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
JP6797111B2 (ja) * 2014-09-30 2020-12-09 インターベット インターナショナル ベー． フェー． イヌｐｄ−ｌ１と結合するｐｄ−ｌ１抗体
KR101619862B1 (ko) * 2014-09-30 2016-05-12 주식회사 녹십자 간접효소면역측정법을 이용하는 인간 Fc 포함 단백질의 역가 측정키트 및 이를 이용한 Fc 포함 단백질의 역가 측정방법
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4029508A1 (en) 2014-10-10 2022-07-20 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonists and checkpoint inhibitors
JP6877339B2 (ja) 2014-10-14 2021-05-26 ノバルティス アーゲー Ｐｄ−ｌ１に対する抗体分子およびその使用
HRP20210809T8 (hr) 2014-10-29 2021-09-17 Bicyclerd Limited Biciklični peptidni ligandi specifični za mt1-mmp
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
CA2964276A1 (en) 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
DK3220926T3 (da) 2014-11-17 2025-03-24 Adicet Therapeutics Inc Konstruerede gamma-delta-t-celler
EP3227311B1 (en) 2014-12-05 2022-02-02 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
LT3230320T (lt) 2014-12-09 2021-01-11 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną
LT3233843T (lt) 2014-12-16 2019-12-10 Novartis Ag Izoksazolo hidroksamido rūgšties junginiai, kaip lpxc inhibitoriai
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
EP3250588A1 (en) 2015-01-29 2017-12-06 Board of Trustees of Michigan State University Cryptic polypeptides and uses thereof
EP3254110B1 (en) 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016170541A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP3258943B1 (en) 2015-02-18 2021-05-12 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
RU2742312C1 (ru) * 2015-02-26 2021-02-04 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
US10800846B2 (en) * 2015-02-26 2020-10-13 Merck Patent Gmbh PD-1/PD-L1 inhibitors for the treatment of cancer
ES2789331T3 (es) 2015-03-02 2020-10-26 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
EP3067062A1 (en) * 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
PE20171790A1 (es) 2015-03-23 2017-12-28 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos
WO2016160792A1 (en) * 2015-03-30 2016-10-06 Stcube & Co., Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
HK1247922A1 (zh) 2015-04-03 2018-10-05 Bristol-Myers Squibb Company 用於治疗癌症的吲哚胺2，3-双加氧酶抑制剂
US10842848B2 (en) 2015-04-07 2020-11-24 Cytlimic Inc. Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
US11319359B2 (en) 2015-04-17 2022-05-03 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
DK3283107T3 (da) 2015-04-17 2020-08-31 Bristol Myers Squibb Co Sammensætninger omfattende en kombination af ipilimumab og nivolumab
WO2016183183A1 (en) 2015-05-11 2016-11-17 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
ES2815683T3 (es) 2015-05-11 2021-03-30 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016183115A1 (en) 2015-05-12 2016-11-17 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
WO2016181348A1 (en) 2015-05-14 2016-11-17 Pfizer Inc. Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
EP4086264B1 (en) 2015-05-18 2023-10-25 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
MA42133A (fr) 2015-05-21 2021-06-02 Chemocentryx Inc Modulateurs du ccr2
BR112017024899A2 (pt) 2015-05-21 2018-11-13 Harpoon Therapeutics, Inc. proteínas de ligação trispecíficas e métodos de uso.
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
TWI715587B (zh) * 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
DK3303396T5 (da) 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
CN107613980A (zh) 2015-05-31 2018-01-19 源生公司 用于免疫疗法的组合组合物
JP2018516947A (ja) * 2015-06-09 2018-06-28 レクサン ファーマシューティカルズ インコーポレイテッド フルオロシクロペンテニルシトシンの使用および調製のプロセス
US10696745B2 (en) 2015-06-11 2020-06-30 Wuxi Biologics (Shanghai) Co. Ltd. Anti-PD-L1 antibodies
CN106243225B (zh) * 2015-06-11 2021-01-19 智翔（上海）医药科技有限公司 新型抗-pd-l1抗体
JP2018516969A (ja) 2015-06-12 2018-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
US10869924B2 (en) * 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
IL256080B2 (en) 2015-06-17 2025-06-01 Genentech Inc Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
DK3313879T3 (da) * 2015-06-24 2022-03-14 Hoffmann La Roche Anti-transferrinreceptor-antistoffer med tilpasset affinitet
KR20180021833A (ko) 2015-06-29 2018-03-05 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
JP6654207B2 (ja) 2015-06-29 2020-02-26 オーエスイー・イミュノセラピューティクス 短鎖ペプチド抗腫瘍ワクチンを用いて早期のｔメモリー応答を誘発する方法。
FI3858859T3 (fi) 2015-07-14 2025-12-04 Bristol Myers Squibb Co Menetelmä syövän hoitamiseksi käyttäen immunivasteen vapauttajaa; vasta-ainetta, joka sitoutuu ohjelmoidun solukuoleman 1 reseptoriin (pd-1) tai ohjelmoidun solukuoleman ligandi 1:een (pd-l1)
NZ739503A (en) 2015-07-16 2023-06-30 Bioxcel Therapeutics Inc A novel approach for treatment of cancer using immunomodulation
WO2017019757A1 (en) 2015-07-28 2017-02-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP2018525415A (ja) 2015-08-25 2018-09-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｇｆベータ受容体アンタゴニスト
CA2994184A1 (en) 2015-09-04 2017-03-09 Rexahn Pharmaceuticals, Inc. Quinoxalinyl-piperazinamide methods of use
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
CN106540255A (zh) * 2015-09-18 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用
EP3356551B1 (en) 2015-09-29 2020-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the metabolic status of b-lymphomas
CA3000386A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3356406A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CN106565836B (zh) * 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
ES2994611T3 (en) 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
SI3370733T1 (sl) 2015-11-02 2021-11-30 Board Of Regents The University Of Texas System Postopek za aktivacijo CD40 in blokada imunske nadzorne točke
CN107614529B (zh) * 2015-11-17 2019-11-12 苏州盛迪亚生物医药有限公司 Pd-l1抗体、其抗原结合片段及其医药用途
US11072657B2 (en) 2015-11-18 2021-07-27 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
CN108738324B (zh) 2015-11-19 2022-06-21 百时美施贵宝公司 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
US10858432B2 (en) 2015-12-02 2020-12-08 Stcube, Inc. Antibodies specific to glycosylated PD-1 and methods of use thereof
ES2863225T3 (es) 2015-12-03 2021-10-11 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos purinos como moduladores del sting
MY195681A (en) * 2015-12-07 2023-02-03 Merck Patent Gmbh Aqueous Pharmaceutical Formulation Comprising Anti-Pd-L1 Antibody Avelumab
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017106291A1 (en) 2015-12-15 2017-06-22 Bristol-Myers Squibb Company Cxcr4 receptor antagonists
CA3008838A1 (en) * 2015-12-17 2017-06-22 University Of Maryland, Baltimore County A recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression
EP4424322A3 (en) 2015-12-17 2025-04-16 Novartis AG Antibody molecules to pd-1 and uses thereof
GB201522311D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
AU2016370813A1 (en) 2015-12-18 2018-06-28 Novartis Ag Antibodies targeting CD32b and methods of use thereof
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
SI3394093T1 (sl) 2015-12-23 2022-05-31 Modernatx, Inc. Metode uporabe liganda OX40, ki kodira polinukleotid
CN105461808B (zh) * 2015-12-24 2019-03-19 长春金赛药业股份有限公司 单克隆抗体及其应用
US20200264165A1 (en) 2016-01-04 2020-08-20 Inserm (Institut National De La Sante Et De Larecherche Medicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
US20190008869A1 (en) 2016-01-13 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of an Antifolate and a BTK Inhibitor
EP3411068A4 (en) * 2016-02-02 2020-01-29 Kadmon Corporation, LLC BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR
KR20180110141A (ko) 2016-02-18 2018-10-08 엔리벡스 테라퓨틱스 리미티드 암을 치료하기 위한 면역요법과 사이토카인 조절 요법의 조합
SG11201806863WA (en) 2016-02-19 2018-09-27 Novartis Ag Tetracyclic pyridone compounds as antivirals
KR20190003938A (ko) 2016-02-25 2019-01-10 셀 메디카 스위처란트 아게 면역치료를 위한 변형된 세포
ES2801873T3 (es) * 2016-03-04 2021-01-14 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Anticuerpo de PDL-1, composición farmacéutica del mismo y sus usos
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
EP3426271B1 (en) 2016-03-10 2025-08-27 CG Oncology, Inc. Methods of treating solid tumors by combination therapy
WO2017159699A1 (en) 2016-03-15 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
EP3429693B1 (en) 2016-03-15 2023-08-23 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
CN107216389B (zh) * 2016-03-18 2022-03-29 和迈生物科技有限公司 抗pd-l1纳米抗体及其编码序列和用途
KR20180127971A (ko) * 2016-03-23 2018-11-30 맵스페이스 바이오사이언시즈 (쑤저우) 컴퍼니 리미티드 신규 항-pd-l1 항체
FI3433257T3 (fi) 2016-03-24 2024-01-08 Novartis Ag Alkynyylinukleosidianalogeja ihmisen rinoviruksen estäjinä
EP3436475A1 (en) 2016-03-29 2019-02-06 STCube & Co., Inc. Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
CN109195991B (zh) 2016-03-29 2023-10-31 斯特库比股份有限公司 对糖基化pd-l1特异的双重功能抗体及其使用方法
EP3225253A1 (en) 2016-04-01 2017-10-04 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
TWI808938B (zh) 2016-04-07 2023-07-21 美商卡默森屈有限公司 藉由投予ccr1拮抗劑與pd-1抑制劑或pd-l1抑制劑之組合減少腫瘤負荷
CA3020830A1 (en) 2016-04-13 2017-10-19 Vivia Biotech, S.L Ex vivo bite.rtm. activated t cells
RS66062B1 (sr) 2016-04-14 2024-11-29 Ose Immunotherapeutics Nova anti-sirpa antitela i njihove terapijske primene
CN109311989A (zh) * 2016-04-14 2019-02-05 创新微技术公司 在癌症疗法的治疗决定中的pd-l1表达的应用方法
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
CN105695406A (zh) * 2016-04-27 2016-06-22 天津普瑞赛尔生物科技有限公司 制备具有高效肿瘤杀伤性dc-cik免疫细胞的方法及制得的dc-cik免疫细胞
KR20190004742A (ko) 2016-05-04 2019-01-14 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
CN109415320A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
JP2019516682A (ja) 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
CN109414420A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
JP2019522627A (ja) 2016-05-04 2019-08-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
EP3452483B1 (en) 2016-05-05 2020-04-01 GlaxoSmithKline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
CA3021669A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
CN110072533B (zh) 2016-05-12 2024-04-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
SG11201809381XA (en) 2016-05-18 2018-12-28 Modernatx Inc Polynucleotides encoding interleukin-12 (il12) and uses thereof
EP4137509A1 (en) 2016-05-18 2023-02-22 ModernaTX, Inc. Combinations of mrnas encoding immune modulating polypeptides and uses thereof
KR20190019068A (ko) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
WO2017201432A2 (en) 2016-05-19 2017-11-23 Jounaidi Youssef Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7194022B2 (ja) 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
JP2019516748A (ja) * 2016-05-26 2019-06-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ がんを治療するためのｐｄ−１／ｐｄ−ｌ１阻害剤
CA3024508A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
EP3464368B1 (en) 2016-06-02 2023-06-28 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
RS64388B1 (sr) 2016-06-02 2023-08-31 Bristol Myers Squibb Co Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfoma
CN109475634A (zh) 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
KR102515509B1 (ko) 2016-06-03 2023-03-28 브리스톨-마이어스 스큅 컴퍼니 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
KR20190015408A (ko) 2016-06-03 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
BR112018075598A2 (pt) 2016-06-08 2019-03-26 Glaxosmithkline Intellectual Property Development Limited compostos químicos
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
MX2018015584A (es) 2016-06-13 2019-09-18 I Mab Anticuerpos anti-pd-l1 y usos de los mismos.
CN109414500B (zh) * 2016-06-13 2022-02-25 奥美药业有限公司 治疗和诊断用pd-l1特异性单克隆抗体
JP6941630B2 (ja) 2016-06-14 2021-09-29 ノバルティス アーゲー 抗菌剤としての（ｒ）−４（５−（シクロプロピルエチニル）イソオキサゾール−３−イル）−ｎ−ヒドロキシ−２−メチル−２−（メチルスルホニル）ブタンアミドの結晶形
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
CA3027302A1 (en) 2016-06-20 2017-12-28 F-Star Beta Limited Binding members(1)
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
SG11201810509PA (en) * 2016-06-20 2018-12-28 Kymab Ltd Anti-pd-l1 antibodies
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
AU2016410294A1 (en) 2016-06-24 2019-01-03 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of NKG2D ligands
AU2017290709B2 (en) * 2016-06-29 2024-08-01 Checkpoint Therapeutics, Inc. PD-L1-specific antibodies and methods of using the same
CN109983121A (zh) 2016-06-30 2019-07-05 昂克诺斯公司 治疗性多肽的假型化溶瘤病毒递送
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
BR112019000431A2 (pt) 2016-07-14 2019-07-09 Bristol-Myers Squibb Company anticorpos contra tim3 e usos dos mesmos
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
KR20190028540A (ko) 2016-07-20 2019-03-18 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Perk 억제제로서의 이소퀴놀린 유도체
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
US20210369746A1 (en) 2016-08-01 2021-12-02 Molecular Templates, Inc. Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
EP3369745B1 (en) * 2016-08-04 2021-09-29 Innovent Biologics (Suzhou) Co., Ltd. Anti-pd-l1 nanobody and use thereof
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
EP3496707A4 (en) * 2016-08-09 2020-03-25 Angimmune, LLC Treatment of cancer using a combination of immunomodulation and check point inhibitors
WO2018029367A1 (en) * 2016-08-12 2018-02-15 Merck Patent Gmbh Combination therapy for cancer
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
JP2019528300A (ja) 2016-08-26 2019-10-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法
CN106248955A (zh) * 2016-09-03 2016-12-21 长春工业大学 一种检测人源化pd‑l1抗体的试剂盒
TW201811788A (zh) 2016-09-09 2018-04-01 瑞士商諾華公司 作為抗病毒劑之多環吡啶酮化合物
MX2019002728A (es) 2016-09-09 2019-08-16 Tg Therapeutics Inc Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres.
WO2018048975A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
US11673971B2 (en) 2016-09-23 2023-06-13 Marengo Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
TWI773694B (zh) 2016-10-11 2022-08-11 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
CN109982711A (zh) 2016-10-11 2019-07-05 Cytlimic公司 药物
BR112018013653B1 (pt) * 2016-10-15 2020-12-15 Innovent Biologics (Suzhou) Co., Ltd Anticorpos anti-pd-1, processo para produção do mesmo e uso dos anticorpos
WO2018073753A1 (en) 2016-10-18 2018-04-26 Novartis Ag Fused tetracyclic pyridone compounds as antivirals
KR20240019398A (ko) 2016-10-28 2024-02-14 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
CN117088979A (zh) * 2016-10-30 2023-11-21 上海复宏汉霖生物技术股份有限公司 抗-pd-l1抗体及变异体
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11117968B2 (en) 2016-11-03 2021-09-14 Bristol-Myers Squibb Company Activatable anti-CTLA-4 antibodies and uses thereof
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
CN110520534A (zh) * 2016-11-09 2019-11-29 恩根尼公司 程序性死亡配体1的肠表达
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
CN106496327B (zh) * 2016-11-18 2019-01-15 昆山百尔泰生物科技有限公司 针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
KR20190090823A (ko) 2016-12-01 2019-08-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조합 요법
JP2020500878A (ja) 2016-12-01 2020-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 併用療法
US20190358262A1 (en) 2016-12-03 2019-11-28 Juno Therapeutics, Inc. Methods for modulation of car-t cells
MA50948A (fr) 2016-12-07 2020-10-14 Agenus Inc Anticorps et procédés d'utilisation de ceux-ci
AU2017373944B2 (en) 2016-12-07 2022-02-03 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
WO2018110515A1 (ja) 2016-12-12 2018-06-21 第一三共株式会社 抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
BR112019012154A2 (pt) 2016-12-14 2019-11-12 Janssen Biotech, Inc. domínios do tipo iii da fibronectina de ligação a cd8a
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
WO2018112360A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
WO2018112364A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018119114A1 (en) 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
CN110139922B (zh) 2016-12-22 2021-05-25 香港大学 用于澄清组织的组合物和方法
JP7128529B2 (ja) * 2016-12-23 2022-08-31 アールイーエムディー バイオセラピューティクス，インコーポレイテッド プログラム死リガンド－１（ｐｄ－ｌ１）に結合する抗体を使用する免疫
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3565560B1 (en) 2017-01-09 2024-05-29 OnkosXcel Therapeutics, LLC Predictive and diagnostic methods for prostate cancer
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
KR20190103226A (ko) 2017-01-13 2019-09-04 아게누스 인코포레이티드 Ny-eso-1에 결합하는 t 세포 수용체 및 이의 사용 방법
CA3047600A1 (en) 2017-01-20 2018-07-26 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
SG11201906414VA (en) 2017-01-24 2019-08-27 Pfizer Calicheamicin derivatives and antibody drug conjugates thereof
KR102577036B1 (ko) 2017-01-25 2023-09-08 오제 이뮈노테라프틱스 펩티드 전달용 안정한 에멀젼을 제조하는 방법
TWI774726B (zh) 2017-01-25 2022-08-21 英屬開曼群島商百濟神州有限公司 (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
WO2018140890A1 (en) * 2017-01-29 2018-08-02 Zequn Tang Methods of immune modulation against foreign and/or auto antigens
KR20190115053A (ko) 2017-02-10 2019-10-10 노파르티스 아게 1-(4-아미노-5-브로모-6-(1h-피라졸-1-일)피리미딘-2-일)-1h-피라졸-4-올 및 암 치료에 있어서의 이의 용도
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
CN108456251A (zh) * 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 抗pd-l1抗体及其应用
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
EP4389226A3 (en) 2017-02-24 2024-12-18 MacroGenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
EA201992027A1 (ru) 2017-03-06 2020-02-25 Мерк Патент Гмбх Водный состав антитела против pd-l1
EP3372615A1 (en) 2017-03-06 2018-09-12 Merck Patent GmbH Composition comprising avelumab
IL322509A (en) 2017-03-09 2025-10-01 Genmab As Antibodies against PD-L1
WO2018170168A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
CN119161451A (zh) * 2017-03-16 2024-12-20 高山免疫科学股份有限公司 Pd-l1变体免疫调节蛋白及其用途
US20210186982A1 (en) 2017-03-24 2021-06-24 Universite Nice Sophia Antipolis Methods and compositions for treating melanoma
JP2020512382A (ja) * 2017-03-29 2020-04-23 グリコトープ ゲーエムベーハー Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体
EP3600410A1 (en) 2017-03-30 2020-02-05 Merck Patent GmbH Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
CA3058175A1 (en) 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
CN108728444A (zh) 2017-04-18 2018-11-02 长春华普生物技术股份有限公司 免疫调节性多核苷酸及其应用
US12460208B2 (en) 2017-04-18 2025-11-04 Parr Biotechnology Co., Ltd. Immunomodulatory polynucleotides and uses thereof
CA3058944A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CA3059939A1 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
CN110621341A (zh) 2017-04-26 2019-12-27 百时美施贵宝公司 使二硫键还原最小化的抗体生产方法
AR111419A1 (es) 2017-04-27 2019-07-10 Novartis Ag Compuestos fusionados de indazol piridona como antivirales
CA3059769A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
WO2018204363A1 (en) 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
AR111658A1 (es) 2017-05-05 2019-08-07 Novartis Ag 2-quinolinonas tricíclicas como agentes antibacteriales
CN110831580A (zh) 2017-05-09 2020-02-21 特沙诺有限公司 用于治疗癌症的组合疗法
JP7264827B2 (ja) 2017-05-12 2023-04-25 江蘇恒瑞医薬股▲ふん▼有限公司 ＴＧＦ－β受容体含有融合タンパク質およびそれらの医薬的用途
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
JP7274426B2 (ja) 2017-05-16 2023-05-16 ブリストル－マイヤーズ スクイブ カンパニー 抗ｇｉｔｒアゴニスト抗体での癌の処置
EP3634417B1 (en) 2017-05-17 2023-07-12 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
US11421011B2 (en) 2017-05-18 2022-08-23 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
MX2019012038A (es) 2017-05-30 2019-11-18 Bristol Myers Squibb Co Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
AU2018275209A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
IL322104A (en) 2017-05-30 2025-09-01 Bristol Myers Squibb Co Treatment of lag-3 positive tumors
JOP20190279A1 (ar) 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
CN110799213A (zh) 2017-06-01 2020-02-14 康姆普根有限公司 三联组合抗体疗法
EP3630839A1 (en) 2017-06-01 2020-04-08 Xencor, Inc. Bispecific antibodies that bind cd 123 cd3
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
KR20240149982A (ko) 2017-06-01 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 종양을 치료하는 방법
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
CN110869049A (zh) 2017-06-09 2020-03-06 葛兰素史克知识产权开发有限公司 组合疗法
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CN111201035A (zh) 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
US11312783B2 (en) 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
KR20200019865A (ko) 2017-06-22 2020-02-25 노파르티스 아게 암 치료에 사용하기 위한 il-1베타 결합 항체
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
CN116535508A (zh) * 2017-06-25 2023-08-04 西雅图免疫公司 抗pd-l1抗体及其制备和使用方法
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
KR20200022447A (ko) 2017-06-27 2020-03-03 노파르티스 아게 항-tim-3 항체의 투여 요법 및 그의 용도
WO2019003164A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
EP3644993B1 (en) 2017-06-30 2023-08-02 Bristol-Myers Squibb Company Amorphous and crystalline forms of ido inhibitors
JP2020525512A (ja) 2017-07-03 2020-08-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物
EP3649106A1 (en) 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019014402A1 (en) 2017-07-14 2019-01-17 Innate Tumor Immunity, Inc. MODULATORS OF NLRP3
EP3431088A1 (en) * 2017-07-20 2019-01-23 Paris Sciences et Lettres - Quartier Latin Mntbap for use in inducing a transient immune tolerance
KR20200031659A (ko) 2017-07-20 2020-03-24 노파르티스 아게 항-lag-3 항체의 투여 요법 및 그의 용도
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019023624A1 (en) 2017-07-28 2019-01-31 Bristol-Myers Squibb Company PREDICTIVE PERIPHERAL BLOOD BIOMARKER FOR INHIBITORS OF CONTROL POINTS
CN113896797B (zh) 2017-08-01 2023-05-09 Ab工作室有限公司 双特异性抗体及其用途
CA3071211A1 (en) 2017-08-04 2019-02-07 Genmab A/S Binding agents binding to pd-l1 and cd137 and use thereof
WO2019025811A1 (en) 2017-08-04 2019-02-07 Bicycletx Limited SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
CN119285770A (zh) * 2017-08-09 2025-01-10 奥里尼斯生物科学有限公司 Pd-1和pd-l1结合剂
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019036657A1 (en) 2017-08-17 2019-02-21 Kyn Therapeutics AHR INHIBITORS AND USES THEREOF
TWI785098B (zh) 2017-08-18 2022-12-01 開曼群島商科賽睿生命科學公司 Tg02之多晶型
MA49950A (fr) 2017-08-25 2020-07-01 Five Prime Therapeutics Inc Anticorps anti-b7-h4 et leurs procédés d'utilisation
JP2020531854A (ja) 2017-08-28 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の治療および診断のためのｔｉｍ−３アンタゴニスト
WO2019046856A1 (en) 2017-09-04 2019-03-07 Agenus Inc. T-CELL RECEPTORS THAT BIND TO SPECIFIC PHOSPHOPEPTIDES OF MIXED LINEAR LEUKEMIA (MLL) AND METHODS OF USE THEREOF
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
JP7382922B2 (ja) 2017-09-20 2023-11-17 中外製薬株式会社 Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
IL273432B (en) 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein compounds and their uses
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
BR112020005284A2 (pt) 2017-09-25 2020-09-24 Chemocentryx, Inc. terapia de combinação usando um antagonista do receptor de quimiocina 2 (ccr2) e um inibidor de pd-1/pd-l1
BR112020005938A2 (pt) * 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
CN111182923A (zh) 2017-10-06 2020-05-19 特沙诺有限公司 组合疗法及其用途
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
EP3470429A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
JP7438939B2 (ja) 2017-10-10 2024-02-27 ヌマブ セラピューティクス アクチェンゲゼルシャフト Ｃｄ１３７を標的とする抗体とその利用方法
EP3694879A1 (en) * 2017-10-10 2020-08-19 Numab Therapeutics AG Antibodies targeting pdl1 and methods of use thereof
CA3075969A1 (en) 2017-10-10 2019-04-18 Numab Therapeutics AG Multispecific antibody
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
RU2020113246A (ru) 2017-10-13 2021-11-15 Мерк Патент Гмбх Комбинация ингибитора parp и антагониста, связывающегося с осью pd-1
EP3694881A1 (en) 2017-10-13 2020-08-19 OSE Immunotherapeutics Modified anti-sirpa antibodies and uses thereof
KR102425983B1 (ko) 2017-10-13 2022-07-29 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
CN111247169A (zh) 2017-10-15 2020-06-05 百时美施贵宝公司 治疗肿瘤的方法
AU2018351000B2 (en) 2017-10-18 2023-11-30 Alpine Immune Sciences, Inc. Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
WO2019077062A1 (en) 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
MX2020004074A (es) 2017-10-19 2020-10-16 Debiopharm Int Sa Producto de combinacion para el tratamiento de cancer.
US11685782B2 (en) 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
EP3704159A1 (en) 2017-11-01 2020-09-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
EP3707138B1 (en) 2017-11-06 2022-07-13 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
US20210292415A1 (en) 2017-11-06 2021-09-23 Bristol-Myers Squibb Company Methods of treating a tumor
CA3082287C (en) 2017-11-14 2023-02-28 Pfizer Inc. Ezh2 inhibitor combination therapies
WO2019099744A1 (en) 2017-11-15 2019-05-23 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF δ3 γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
EP3710455A1 (en) 2017-11-17 2020-09-23 Novartis AG Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
WO2019101347A1 (en) 2017-11-27 2019-05-31 Ose Immunotherapeutics Improved treatment of cancer
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
KR20200096253A (ko) 2017-11-30 2020-08-11 노파르티스 아게 Bcma-표적화 키메라 항원 수용체, 및 이의 용도
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
CN111433210A (zh) 2017-12-20 2020-07-17 诺华股份有限公司 作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
AU2018396964C1 (en) 2017-12-28 2024-10-03 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against PD-L1
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
CA3087149A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
EP3735590A1 (en) 2018-01-04 2020-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
WO2019136112A1 (en) 2018-01-05 2019-07-11 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
IL275898B2 (en) 2018-01-08 2025-05-01 Chemocentryx Inc Methods for treating solid tumors with CCR2 antagonists
US12539308B2 (en) 2018-01-08 2026-02-03 The Trustees Of The University Of Pennsylvania Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
MX2020007406A (es) 2018-01-10 2020-09-14 Jiangsu Hengrui Medicine Co Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
JP2021510697A (ja) 2018-01-12 2021-04-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ がん処置のための坑ｉｌ−８抗体及び坑ｐｄ−１抗体を用いる組合せ治療
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12129297B2 (en) 2018-01-12 2024-10-29 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
US20210363242A1 (en) 2018-01-16 2021-11-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
KR20200112904A (ko) 2018-01-22 2020-10-05 브리스톨-마이어스 스큅 컴퍼니 암을 치료하는 조성물 및 방법
WO2019144126A1 (en) 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
CN111867581B (zh) 2018-01-29 2023-12-26 默克专利股份有限公司 Gcn2抑制剂及其用途
SG11202006701TA (en) 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
MA54118A (fr) 2018-01-31 2021-09-15 Celgene Corp Polythérapie utilisant une thérapie cellulaire adoptive et un inhibiteur de point de contrôle
CA3090652A1 (en) 2018-02-06 2019-08-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
WO2019157124A1 (en) 2018-02-08 2019-08-15 Bristol-Myers Squibb Company Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019161054A1 (en) 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
SG11202007821WA (en) 2018-02-21 2020-09-29 Five Prime Therapeutics Inc B7-h4 antibody formulations
WO2019162325A1 (en) 2018-02-21 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
MX2020008791A (es) 2018-02-23 2021-01-08 Bicycletx Ltd Ligandos de peptidos biciclicos multimericos.
WO2019166951A1 (en) 2018-02-28 2019-09-06 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
JP2021516051A (ja) 2018-03-02 2021-07-01 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体及びその使用方法
MX2020009290A (es) 2018-03-05 2020-09-28 Arcus Biosciences Inc Inhibidores de la arginasa.
CN112218658A (zh) 2018-03-12 2021-01-12 国家健康科学研究所 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
KR20210006338A (ko) 2018-03-13 2021-01-18 오제 이뮈노테라프틱스 항-인간 SIRPa v1 항체의 이용 및 항-SIRPa v1 항체를 생산하는 방법
MX2020009478A (es) 2018-03-14 2020-10-22 Merck Patent Gmbh Compuestos y sus usos para tratar tumores en un paciente.
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
AU2019235842B2 (en) 2018-03-14 2022-02-03 Surface Oncology, Inc. Antibodies that bind CD39 and uses thereof
MX2020009743A (es) * 2018-03-19 2020-10-08 Abeome Corp Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos.
CA3092589A1 (en) 2018-03-21 2019-09-26 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
EP3768317A4 (en) 2018-03-22 2021-12-22 Surface Oncology, Inc. ANTI-IL-27 ANTIBODIES AND USES THEREOF
CN117586412A (zh) 2018-03-23 2024-02-23 得克萨斯州大学系统董事会 针对人pd-l1和pd-l2的双重特异性抗体及其使用方法
EP4501355A3 (en) 2018-03-23 2025-04-30 Board Of Regents, The University Of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
WO2019182888A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Human pd-l2 antibodies and methods of use therefor
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
US11952424B2 (en) 2018-03-30 2024-04-09 Merus N.V. Multivalent antibody
JP7680208B2 (ja) 2018-04-04 2025-05-20 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ２７抗体およびその使用
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
JP2021521182A (ja) 2018-04-12 2021-08-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3781162A1 (en) 2018-04-16 2021-02-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
CN112292185B (zh) 2018-04-17 2025-07-29 塞德斯医疗公司 抗cd27和抗pd-l1抗体及双特异性构建体
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
MA52289A (fr) 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
CN119286871A (zh) 2018-04-19 2025-01-10 查美特制药公司 合成rig-i样受体激动剂
CA3097865A1 (en) 2018-04-25 2019-10-31 Innate Tumor Immunity, Inc. Nlrp3 modulators
KR20210005646A (ko) 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
KR20210006405A (ko) 2018-05-04 2021-01-18 메르크 파텐트 게엠베하 암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3801617A1 (en) 2018-06-01 2021-04-14 Novartis Ag Dosing of a bispecific antibody that bind cd123 and cd3
WO2019232533A1 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Combination treatments of hsp90 inhibitors for enhancing tumor immunogenicity and methods of use thereof
US11492409B2 (en) 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
EP3810192A1 (en) * 2018-06-22 2021-04-28 Vyriad Methods of treating cancer using combination therapy
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
US11866430B2 (en) 2018-06-27 2024-01-09 Bristol-Myers Squibb Company Naphthyridinone compounds useful as T cell activators
WO2020006018A1 (en) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as t cell activators
KR102216576B1 (ko) 2018-06-29 2021-02-17 국민대학교 산학협력단 Pd-1과 결합력이 증가된 pd-l1 변이체
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
SG11202100096XA (en) 2018-07-09 2021-02-25 Five Prime Therapeutics Inc Antibodies binding to ilt4
CA3105942A1 (en) 2018-07-09 2020-01-16 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020012334A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN112996910A (zh) * 2018-07-11 2021-06-18 动量制药公司 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法
MX2021000213A (es) 2018-07-11 2021-03-25 Five Prime Therapeutics Inc Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acidico.
US12398181B2 (en) 2018-07-11 2025-08-26 The Brigham And Women's Hospital, Inc. Methods and compositions for delivery of agents across the blood-brain barrier
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020011964A1 (en) 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind pd-l1 and cd137
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
IL280002B2 (en) 2018-07-12 2025-05-01 F Star Beta Ltd Antibody molecules that bind CD137 and OX40
WO2020014583A1 (en) 2018-07-13 2020-01-16 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
JP7522720B2 (ja) 2018-07-18 2024-07-25 アーカス バイオサイエンシズ インコーポレイティド アゾロピリミジン化合物の固体形態
US11214619B2 (en) 2018-07-20 2022-01-04 Surface Oncology, Inc. Anti-CD112R compositions and methods
US12145927B2 (en) 2018-07-23 2024-11-19 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12059420B2 (en) 2018-07-23 2024-08-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020020307A1 (en) 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
EP4667493A2 (en) 2018-07-26 2025-12-24 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
JP7303527B2 (ja) 2018-07-31 2023-07-05 国立大学法人 東京大学 新たな結合特異性を抗体に付与する超汎用法
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
EP3837014B1 (en) 2018-08-16 2022-10-19 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
SG11202101486RA (en) 2018-08-16 2021-03-30 Innate Tumor Immunity Inc Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
ES2974964T3 (es) 2018-08-16 2024-07-02 Innate Tumor Immunity Inc Moduladores de NLRP3 derivados de imidazo[4,5-c]quinolina
WO2020038379A1 (en) 2018-08-20 2020-02-27 1Globe Biomedical Co., Ltd. Novel cancer immunotherapy antibody compositions
EP3841121A2 (en) 2018-08-20 2021-06-30 Pfizer Inc. Anti-gdf15 antibodies, compositions and methods of use
EP3843849A1 (en) 2018-08-27 2021-07-07 Pieris Pharmaceuticals GmbH Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
WO2020048942A1 (en) 2018-09-04 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
US11331269B2 (en) 2018-09-06 2022-05-17 Massachusetts Institute Of Technology Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
CA3111562A1 (en) * 2018-09-07 2020-04-02 The General Hospital Corporation Compositions and methods for immune checkpoint inhibition
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
CN109053891B (zh) * 2018-09-17 2021-12-21 苏州泓迅生物科技股份有限公司 一种抗pd-l1抗体及其制备方法和应用
WO2020058372A1 (en) 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
AU2019342749B2 (en) 2018-09-20 2025-07-10 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CN113286614A (zh) * 2018-09-26 2021-08-20 默克专利股份有限公司 用于治疗癌症的pd-1拮抗剂、atr抑制剂和铂化物质的组合
EP3856350A1 (en) 2018-09-27 2021-08-04 Marengo Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
EP3860578A1 (en) 2018-10-01 2021-08-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of inhibitors of stress granule formation for targeting the regulation of immune responses
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
CN112839962A (zh) 2018-10-09 2021-05-25 百时美施贵宝公司 用于治疗癌症的抗mertk抗体
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
US11377477B2 (en) 2018-10-12 2022-07-05 Xencor, Inc. PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
US20210348238A1 (en) 2018-10-16 2021-11-11 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
PT4445958T (pt) 2018-10-19 2025-11-26 Bristol Myers Squibb Co Terapia de associação para melanoma
AU2019366321A1 (en) 2018-10-22 2021-05-13 Glaxosmithkline Intellectual Property Development Limited Dosing
JP2022505647A (ja) 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍の処置方法
CN113365664A (zh) 2018-10-29 2021-09-07 梅尔莎纳医疗公司 具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
CA3117371A1 (en) 2018-11-01 2020-05-07 Merck Patent Gmbh Methods of administering anti-tim-3 antibodies
AU2019371457A1 (en) 2018-11-01 2021-05-20 Merck Patent Gmbh Anti-TIM-3 antibodies
EP3876940A1 (en) 2018-11-05 2021-09-15 Pfizer Inc. Combinations for treating cancer
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
CN113454111A (zh) 2018-11-06 2021-09-28 健玛保 抗体配制剂
US20220001026A1 (en) 2018-11-08 2022-01-06 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
BR112021008288A2 (pt) 2018-11-09 2021-08-10 Jiangsu Hengrui Medicine Co., Ltd. composição farmacêutica de proteína de fusão do receptor tgf-ss e uso da mesma
US20220010017A1 (en) 2018-11-14 2022-01-13 Bayer Aktiengesellschaft Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
CN113038939A (zh) 2018-11-14 2021-06-25 瑞泽恩制药公司 损害内施用pd-1抑制剂用于治疗皮肤癌
ES3034676T3 (en) 2018-11-16 2025-08-21 Arcus Biosciences Inc Inhibitors of arg1 and/or arg2
JP2022507606A (ja) 2018-11-16 2022-01-18 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
JP7520003B2 (ja) 2018-11-16 2024-07-22 ブリストル－マイヤーズ スクイブ カンパニー 抗ｎｋｇ２ａ抗体およびその使用
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
US20220016277A1 (en) 2018-11-20 2022-01-20 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
US20230183379A1 (en) 2018-11-20 2023-06-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
EP3886842A1 (en) 2018-11-26 2021-10-06 Debiopharm International SA Combination treatment of hiv infections
US20220018828A1 (en) 2018-11-28 2022-01-20 Inserm (Institut National De La Santé Et La Recherche Médicale Methods and kit for assaying lytic potential of immune effector cells
TWI824069B (zh) 2018-11-30 2023-12-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 用於hiv治療之化合物
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
AU2019391097B2 (en) 2018-12-04 2025-07-03 Sumitomo Pharma America, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CN113167802B (zh) 2018-12-04 2025-02-07 百时美施贵宝公司 通过多同位素体反应监测使用样品内校准曲线的分析方法
WO2020115262A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020123011A1 (en) 2018-12-13 2020-06-18 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
EP3897624A1 (en) 2018-12-17 2021-10-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of sulconazole as a furin inhibitor
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
BR112021007968A2 (pt) 2018-12-19 2021-09-08 Bayer Aktiengesellschaft Combinação farmacêutica de anticorpos anti-ceacam6 e tim3
EP3897637A1 (en) 2018-12-20 2021-10-27 Novartis AG Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3897853A1 (en) 2018-12-20 2021-10-27 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
CA3118182A1 (en) 2018-12-21 2020-06-25 Onxeo New conjugated nucleic acid molecules and their uses
CA3119582A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1.beta. binding antibodies
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
CN113227137A (zh) 2018-12-21 2021-08-06 诺华股份有限公司 IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途
CA3124773A1 (en) 2018-12-28 2020-07-02 Transgene M2-defective poxvirus
KR102865929B1 (ko) 2019-01-14 2025-09-29 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
US12338228B2 (en) 2019-01-14 2025-06-24 Innate Tumor Immunity, Inc. NLRP3 modulators
WO2020150113A1 (en) 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
CN113301962A (zh) 2019-01-14 2021-08-24 先天肿瘤免疫公司 用于治疗癌症的杂环nlrp3调节剂
IL284868B2 (en) 2019-01-15 2025-09-01 Inst Nat Sante Rech Med Mutant interleukin-34 (IL-34) polypeptides and their use for medical therapy
US20220117938A1 (en) 2019-01-18 2022-04-21 Dracen Pharmaceuticals, Inc. Combinaton therapy with a don prodrug and an immune checkpoint inhibitor
US12463463B2 (en) 2019-01-28 2025-11-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
WO2020157131A1 (en) 2019-01-30 2020-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
WO2020156500A1 (zh) * 2019-01-31 2020-08-06 正大天晴药业集团股份有限公司 抗pd-l1抗体治疗头颈癌的用途
WO2020161083A1 (en) 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
US20220098674A1 (en) 2019-02-13 2022-03-31 Inserm (Institut National De La Santé Et Dr La Recherch Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
RS65316B1 (sr) 2019-02-18 2024-04-30 Medivir Ab Kombinacija lekova za upotrebu u postupku lečenja raka jetre
MX2021009967A (es) 2019-02-19 2021-11-12 Myst Therapeutics Llc Metodos para producir celulas t autologas utiles para tratar cancer y composiciones de las mismas.
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
BR112021016596A2 (pt) * 2019-02-21 2021-12-21 Eucure Beijing Biopharma Co Ltd Anticorpo anti-pd-l1 e uso do mesmo
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
AU2020228296B2 (en) 2019-02-28 2025-10-02 Regeneron Pharmaceuticals, Inc. Administration of PD-1 inhibitors for treating skin cancer
MX2021010560A (es) 2019-03-06 2021-11-12 Regeneron Pharma Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
US12453738B2 (en) 2019-03-12 2025-10-28 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
CN113795264A (zh) 2019-03-19 2021-12-14 瓦尔希伯伦私人肿瘤研究基金会 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
EP3941463A1 (en) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
CN114269763A (zh) 2019-03-26 2022-04-01 美国密歇根州立大学试剂中心 Stat3的小分子降解剂
US20220195046A1 (en) 2019-03-28 2022-06-23 Bristol-Myers Squibb Company Methods of treating tumor
CN113677402A (zh) 2019-03-28 2021-11-19 百时美施贵宝公司 治疗肿瘤的方法
US20220185831A1 (en) 2019-03-29 2022-06-16 The Regents Of The University Of Michigan Stat3 protein degraders
KR20210144821A (ko) 2019-03-29 2021-11-30 아르커스 바이오사이언시즈 인코포레이티드 규명된 아데노신 지문을 이용한 암의 치료방법
JP7760374B2 (ja) 2019-03-29 2025-10-27 ターンストーン バイオロジクス コーポレイション Ｔ細胞治療薬を生成するためのエクスビボ方法ならびに関連する組成物および方法
EP3947640A4 (en) 2019-04-02 2022-12-14 The Brigham & Women's Hospital, Inc. PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020201753A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
CN120574283A (zh) 2019-04-05 2025-09-02 凯麦拉医疗公司 Stat降解剂和其用途
US20220160692A1 (en) 2019-04-09 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
WO2020208612A1 (en) 2019-04-12 2020-10-15 Vascular Biogenics Ltd. Methods of anti-tumor therapy
EP3956446A1 (en) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
MX2021004897A (es) * 2019-04-26 2021-06-18 I Mab Biopharma Us Ltd Anticuerpos pd-l1 humano.
WO2020221796A1 (en) 2019-04-30 2020-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP3966247B1 (en) * 2019-05-06 2026-01-07 Brown University Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
US20220241412A1 (en) 2019-05-24 2022-08-04 Pfizer Inc. Combination therapies using cdk inhibitors
KR20220016157A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 조합 요법
JP2022534967A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 多腫瘍遺伝子シグネチャーおよびその使用
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
TW202108559A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
CN114206926B (zh) 2019-06-10 2022-06-17 山东博安生物技术股份有限公司 抗PDL1和TGFβ的双功能融合蛋白及其用途
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
CN114008080B (zh) * 2019-06-12 2023-06-09 南京金斯瑞生物科技有限公司 抗pd-l1/抗lag-3多抗原结合蛋白及其使用方法
KR102517872B1 (ko) * 2019-06-12 2023-04-05 (주)아큐레시스바이오 암의 예방 또는 치료용 조성물
WO2020252353A1 (en) 2019-06-12 2020-12-17 Vanderbilt University Amino acid transport inhibitors and the uses thereof
AU2020291936A1 (en) 2019-06-12 2022-02-03 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
EP3990618A4 (en) 2019-06-27 2023-08-09 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS AND ASSOCIATED USES
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
GB201910138D0 (en) * 2019-07-15 2019-08-28 Capella Bioscience Ltd Anti-pd-l1 antibodies
AU2020315401B2 (en) 2019-07-16 2025-05-22 The Regents Of The University Of Michigan Imidazopyrimidines as EED inhibitors and the use thereof
CN114269780B (zh) * 2019-07-19 2024-01-19 北京先通生物医药技术有限公司 一种新型抗pd-l1抗体及其用途
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP2022545735A (ja) 2019-08-27 2022-10-28 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン セレブロンｅ３リガーゼ阻害剤
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
MX2022002315A (es) 2019-08-30 2022-03-25 Agenus Inc Anticuerpos anti-cd96 y sus metodos de uso.
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2021050964A1 (en) 2019-09-13 2021-03-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
US11655303B2 (en) 2019-09-16 2023-05-23 Surface Oncology, Inc. Anti-CD39 antibody compositions and methods
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
US11918649B2 (en) 2019-09-18 2024-03-05 Molecular Templates, Inc. PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
JP2022548078A (ja) 2019-09-18 2022-11-16 モレキュラー テンプレーツ，インク． 志賀毒素ａサブユニット足場を含むｐｄ－ｌ１結合分子
AU2020348849A1 (en) 2019-09-19 2022-04-07 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
BR112022004831A2 (pt) 2019-09-19 2022-06-07 Bristol Myers Squibb Co Anticorpos que se ligam a vista em ph ácido
AU2020350137A1 (en) 2019-09-20 2022-04-28 Merck Patent Gmbh Combination of a poxvirus encoding HPV polypeptides and IL-2 with an anti-PD-L1 antibody
CN114450028A (zh) 2019-09-22 2022-05-06 百时美施贵宝公司 Lag-3拮抗剂治疗的定量空间剖析
TW202521984A (zh) 2019-09-25 2025-06-01 美商表面腫瘤學有限責任公司 抗ｉｌ－２７抗體及其用途
MX2022003487A (es) 2019-09-25 2022-04-25 Bristol Myers Squibb Co Biomarcador compuesto para terapia de cancer.
CN120842223A (zh) 2019-09-26 2025-10-28 诺华股份有限公司 抗病毒吡唑并吡啶酮化合物
ES3053994T3 (en) 2019-09-27 2026-01-28 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
EP3800201A1 (en) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h stimulation enhances nk cell killing activities
US20220354811A1 (en) 2019-10-03 2022-11-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
EP4037700A2 (en) 2019-10-03 2022-08-10 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
WO2021064184A1 (en) 2019-10-04 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company CD71-BINDING FIBRONECTIN TYPE III DOMAINS
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
WO2021074391A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
BR112022007179A2 (pt) 2019-10-21 2022-08-23 Novartis Ag Inibidores de tim-3 e usos dos mesmos
IL292347A (en) 2019-10-21 2022-06-01 Novartis Ag Combination treatments with ventoclax and tim-3 inhibitors
US20220378817A1 (en) 2019-10-23 2022-12-01 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
KR20220088425A (ko) 2019-10-25 2022-06-27 다이이찌 산쿄 가부시키가이샤 항 garp 항체와 면역 조절제의 조합
WO2021083959A1 (en) 2019-10-29 2021-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating uveal melanoma
BR112022008321A2 (pt) 2019-11-04 2022-07-26 Alector Llc Polipeptídeos isolados, polipeptídeo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo, para tratar câncer, para tratar uma doença neurológica ou neurodegenerativa, para repolarizar células supressoras, para repolarizar macrófagos de tumor e para ativar células mieloides em um sujeito e composições farmacêuticas
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
JP2022553851A (ja) 2019-11-08 2022-12-26 ブリストル－マイヤーズ スクイブ カンパニー 黒色腫の処置のためのｌａｇ－３アンタゴニスト
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
BR112022009514A2 (pt) 2019-11-19 2022-08-16 Bristol Myers Squibb Co Compostos úteis como inibidores de proteína helios
WO2021102343A1 (en) 2019-11-22 2021-05-27 Sumitomo Dainippon Pharma Oncology, Inc. Solid dose pharmaceutical composition
JP2023502531A (ja) 2019-11-26 2023-01-24 イケナ オンコロジー， インコーポレイテッド 多形カルバゾール誘導体およびその使用
CA3159071A1 (en) 2019-11-26 2021-06-03 Tamar I. ROSENBAUM Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
EP4065229A1 (en) 2019-11-27 2022-10-05 Myst Therapeutics, LLC Method of producing tumor-reactive t cell composition using modulatory agents
AU2020394122A1 (en) 2019-11-27 2022-06-09 Nec Corporation Pharmaceutical composition
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
JP2023509366A (ja) 2019-12-17 2023-03-08 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
EP4076508A1 (en) 2019-12-19 2022-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions to treat cancers
KR20220118481A (ko) 2019-12-19 2022-08-25 브리스톨-마이어스 스큅 컴퍼니 Dgk 억제제 및 체크포인트 길항제의 조합물
IL293889A (en) 2019-12-20 2022-08-01 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN115297931A (zh) 2019-12-23 2022-11-04 凯麦拉医疗公司 Smarca降解剂和其用途
AU2020414688A1 (en) 2019-12-23 2022-08-18 Bristol-Myers Squibb Company Substituted quinolinonyl piperazine compounds useful as T cell activators
JP7677976B2 (ja) 2019-12-23 2025-05-15 ブリストル－マイヤーズ スクイブ カンパニー Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物
MX2022007130A (es) 2019-12-23 2022-07-11 Bristol Myers Squibb Co Derivados de piperazina sustituidos utiles como activadores de celulas t.
ES3038401T3 (en) 2019-12-23 2025-10-13 Bristol Myers Squibb Co Substituted quinazolinyl compounds useful as t cell activators
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
AU2021206618A1 (en) 2020-01-06 2022-08-18 Hifibio, Inc. Anti-TNFR2 antibody and uses thereof
BR112022013494A2 (pt) 2020-01-07 2022-09-13 Hifibio Hk Ltd Anticorpo anti-galectina-9 e usos do mesmo
CN115244052A (zh) 2020-01-10 2022-10-25 先天肿瘤免疫公司 Nlrp3调节剂
EP4087602A4 (en) 2020-01-10 2023-11-29 The Brigham & Women's Hospital, Inc. Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
WO2021146370A1 (en) 2020-01-15 2021-07-22 Blueprint Medicines Corporation Map4k1 inhibitors
WO2021144657A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
EP4090770A1 (en) 2020-01-17 2022-11-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US20230090446A1 (en) 2020-01-28 2023-03-23 Universite De Strasbourg Antisense oligonucleotide targeting linc00518 for treating melanoma
KR20220133196A (ko) 2020-01-29 2022-10-04 메뤼스 엔.페. 면역 세포 관여 효과를 조절하기 위한 수단 및 방법
IL295093A (en) 2020-01-30 2022-09-01 Ona Therapeutics S L Combination therapy for treatment of cancer and cancer metastasis
WO2021156360A1 (en) 2020-02-05 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
JP2023514152A (ja) 2020-02-06 2023-04-05 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－１０およびその使用
US20230220074A1 (en) 2020-02-18 2023-07-13 Alector Llc Pilra antibodies and methods of use thereof
AU2021226903A1 (en) 2020-02-27 2022-10-20 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive T cells and related compositions thereof
WO2021170777A1 (en) 2020-02-28 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
EP4110407A1 (en) 2020-02-28 2023-01-04 Bristol-Myers Squibb Company Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
WO2021171264A1 (en) 2020-02-28 2021-09-02 Novartis Ag Dosing of a bispecific antibody that binds cd123 and cd3
TW202146393A (zh) 2020-03-03 2021-12-16 美商皮克醫療公司 Eif4e抑制劑及其用途
AU2021230575A1 (en) 2020-03-06 2022-10-20 Celgene Quanticel Research, Inc. Combination of an LSD-1 inhibitor and nivolumab for use in treating SCLC or sqNSCLC
CN115768465A (zh) 2020-03-06 2023-03-07 Ona疗法有限公司 抗cd36抗体及其治疗癌症的用途
US20230140384A1 (en) 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
US12528785B2 (en) 2020-03-19 2026-01-20 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
WO2021188769A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
CA3172697A1 (en) 2020-03-23 2021-09-30 Ruth Yin-Zong LAN Anti-ccr8 antibodies for treating cancer
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
US12522623B2 (en) 2020-03-26 2026-01-13 Regents Of The University Of Michigan Small molecule STAT protein degraders
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
JP2023521465A (ja) 2020-04-14 2023-05-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ＩＣＯＳ抗体とＰＤ－Ｌ１抗体ＴＧＦ－β－受容体融合タンパク質とに基づく癌の併用治療
US12159700B2 (en) 2020-04-22 2024-12-03 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
US20230174619A1 (en) * 2020-04-30 2023-06-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. PD-L1 variants with improved affinity towards PD-1
EP4147052A1 (en) 2020-05-05 2023-03-15 F. Hoffmann-La Roche AG Predicting response to pd-1 axis inhibitors
CN116096405A (zh) 2020-05-12 2023-05-09 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2021239838A2 (en) 2020-05-26 2021-12-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
CN115666724A (zh) 2020-05-26 2023-01-31 瑞泽恩制药公司 通过施用pd-1抑制剂抗体西米普利单抗来治疗宫颈癌的方法
EP4157319A1 (en) 2020-05-28 2023-04-05 Modernatx, Inc. Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
US20230250110A1 (en) 2020-06-03 2023-08-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2021249969A1 (en) 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022003554A1 (en) 2020-07-01 2022-01-06 Pfizer Inc. Biomarkers for pd-1 axis binding antagonist therapy
US20250262293A1 (en) 2020-07-07 2025-08-21 BioNTech SE Therapeutic rna for hpv-positive cancer
WO2022011204A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
WO2022011205A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Androgen receptor protein degraders
EP4189395A1 (en) 2020-07-28 2023-06-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for preventing and treating a cancer
EP4188374A4 (en) 2020-07-30 2024-08-14 Kymera Therapeutics, Inc. METHODS FOR TREATING LYMPHO MUTANTS
CA3189761A1 (en) 2020-08-03 2022-02-10 Gemma Mudd Peptide-based linkers
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2021325225A1 (en) 2020-08-10 2023-03-23 Gv20 Therapeutics Llc Compositions and methods for treating autoimmune diseases and cancers by targeting IGSF8
MX2023001588A (es) 2020-08-17 2023-05-03 Bicycletx Ltd Conjugados biciclo específicos para nectina-4 y usos de estos.
MX2023002123A (es) 2020-08-26 2023-03-15 Regeneron Pharma Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1.
WO2022047046A1 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Methods of detecting trbc1 or trbc2
AU2021331476A1 (en) 2020-08-28 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
US20230303700A1 (en) 2020-08-31 2023-09-28 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
CN111808196B (zh) * 2020-08-31 2020-12-29 北京百奥赛图基因生物技术有限公司 抗pd-1抗体及其用途
CN116194142A (zh) 2020-09-03 2023-05-30 瑞泽恩制药公司 通过施用pd-1抑制剂治疗癌症疼痛的方法
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
CR20230155A (es) 2020-09-14 2023-06-27 Boehringer Ingelheim Int Vacuna heteróloga de estímulo primario
EP4165086A4 (en) * 2020-09-16 2024-07-31 Suzhou Neologics Bioscience Co., Ltd. Pd-l1 antibodies, fusion proteins, and uses thereof
CN111920948B (zh) * 2020-09-25 2021-02-02 安可瑞(山西)生物细胞有限公司 包含免疫细胞的药物组合物用于治疗癌症
CN116601140A (zh) 2020-10-02 2023-08-15 羿尊生物医药股份有限公司 用于皮下施用的包含(s)-2-((s)-2-乙酰氨基-3-(1h-吲哚-3-基)丙酰氨基)-6-重氮基-5-氧代己酸异丙酯的冻干组合物及其用途
EP4225770A1 (en) 2020-10-05 2023-08-16 Bristol-Myers Squibb Company Methods for concentrating proteins
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
MX2023004493A (es) 2020-10-23 2023-05-10 Bristol Myers Squibb Co Terapia de agonista del gen-3 de activacion del linfocito (lag-3) para cancer de pulmon.
US20240148740A1 (en) 2020-10-28 2024-05-09 Ikena Oncology, Inc. Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
EP3992208A1 (en) * 2020-11-03 2022-05-04 Randox Laboratories Ltd Anti-pd-l1 vhh antibodies
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
CA3200878A1 (en) 2020-11-12 2022-05-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
WO2022101463A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
US20230416838A1 (en) 2020-11-16 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
EP4244391A1 (en) 2020-11-16 2023-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
CN117015531A (zh) 2020-12-02 2023-11-07 医肯纳肿瘤学公司 Tead抑制剂及其用途
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
US12180284B2 (en) 2020-12-16 2024-12-31 Molecular Templates, Inc. Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector
CN116964050A (zh) 2020-12-16 2023-10-27 戈萨默生物服务公司 可用作t细胞激活剂的化合物
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
MX2023007734A (es) 2020-12-28 2023-08-21 Bristol Myers Squibb Co Composiciones de anticuerpos y metodos de uso de las mismas.
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
TW202241891A (zh) 2020-12-30 2022-11-01 美商凱麥拉醫療公司 Irak降解劑及其用途
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
WO2022156727A1 (zh) 2021-01-21 2022-07-28 浙江养生堂天然药物研究所有限公司 治疗肿瘤的组合物及方法
US20240141060A1 (en) 2021-01-29 2024-05-02 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
EP4288427A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
BR112023015584A2 (pt) 2021-02-02 2023-10-24 Liminal Biosciences Ltd Antagonistas de gpr84 e usos dos mesmos
CN114452403A (zh) 2021-02-10 2022-05-10 同润生物医药(上海)有限公司 一种含有双功能免疫检查点/TGFβ抑制剂的药物组合
CA3210553A1 (en) 2021-02-12 2022-08-18 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
CN117120090A (zh) 2021-02-12 2023-11-24 林伯士萨顿公司 Hpk1拮抗剂和其用途
MX2023009178A (es) 2021-02-15 2023-08-21 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
EP4301733A1 (en) 2021-03-02 2024-01-10 GlaxoSmithKline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
WO2022187419A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
WO2022187856A1 (en) 2021-03-05 2022-09-09 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
EP4301780A1 (en) 2021-03-05 2024-01-10 Leadartis, S.L. Trimeric polypeptides and uses thereof in the treatment of cancer
EP4305041A1 (en) 2021-03-08 2024-01-17 Blueprint Medicines Corporation Map4k1 inhibitors
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
WO2022194908A1 (en) 2021-03-17 2022-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
MX2023011007A (es) 2021-03-23 2023-12-07 Regeneron Pharma Metodos para tratar el cancer en pacientes inmunosuprimidos o inmunocomprometidos mediante la administracion de un inhibidor de pd-1.
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
WO2022212400A1 (en) 2021-03-29 2022-10-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
US20240166747A1 (en) 2021-03-31 2024-05-23 Glazosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
AU2022253450A1 (en) 2021-04-05 2023-11-16 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
SMT202500281T1 (it) 2021-04-06 2025-09-12 Bristol Myers Squibb Co Composti ossoisoindolinici sostituiti con piridinile
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
KR20240007155A (ko) 2021-04-09 2024-01-16 님버스 클리오, 인코포레이티드 Cbl-b 조절제 및 이의 용도
EP4320155A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
US20240182572A1 (en) 2021-04-09 2024-06-06 Ose Immunotherapeutics Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
CA3215367A1 (en) 2021-04-14 2022-10-20 Swapnil Kulkarni Fn3 domain-sirna conjugates and uses thereof
EP4323409A4 (en) 2021-04-14 2025-04-16 ARO Biotherapeutics Company CD71-BINDING FIBRONECTIN TYPE III DOMAINS
WO2022219080A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
EP4326903A1 (en) 2021-04-23 2024-02-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating cell senescence accumulation related disease
KR20240005809A (ko) 2021-05-07 2024-01-12 서피스 온콜로지, 엘엘씨 항-il-27 항체 및 이의 용도
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
JP2024521712A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ阻害化合物
EP4342492A4 (en) 2021-05-21 2025-01-15 Tianjin Lipogen Technology Co., Ltd PHARMACEUTICAL COMBINATION AND ITS USE
JP2024521706A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ化合物
US20240239907A1 (en) 2021-05-25 2024-07-18 Edelweiss Immune Inc C-X-C Motif Chemokine Receptor 6 (CXCR6) Binding Molecules, and Methods of Using the Same
WO2022247972A2 (es) 2021-05-26 2022-12-01 Centro De Inmunologia Molecular Uso de composiciones terapéuticas para el tratamiento de pacientes con tumores de origen epitelial
US11572412B2 (en) 2021-06-04 2023-02-07 Boehringer Ingelheim International Gmbh Anti-SIRP-alpha antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023280790A1 (en) 2021-07-05 2023-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
KR20240083168A (ko) 2021-07-14 2024-06-11 블루프린트 메디신즈 코포레이션 Map4k1 저해제로서의 헤테로사이클 화합물
WO2023288264A1 (en) 2021-07-15 2023-01-19 Blueprint Medicines Corporation Map4k1 inhibitors
AU2022314735A1 (en) 2021-07-19 2024-02-22 Regeneron Pharmaceuticals, Inc. Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
MX2024001415A (es) 2021-07-30 2024-02-27 Ona Therapeutics S L Anticuerpos anti-cd36 y su uso para tratar el cancer.
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
US12234231B2 (en) 2021-08-25 2025-02-25 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
EP4396229A1 (en) 2021-09-02 2024-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anti-cecam6 antibodies with reduced side-effects
CN118201914A (zh) 2021-09-08 2024-06-14 雷多纳治疗公司 Papd5和/或papd7抑制剂4-氧代-1,4-二氢喹啉-3-甲酸衍生物
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
EP4423249A1 (en) 2021-10-28 2024-09-04 Lyell Immunopharma, Inc. Methods for culturing immune cells
AU2022375806A1 (en) 2021-10-29 2023-12-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
AR127505A1 (es) 2021-10-29 2024-01-31 Kymera Therapeutics Inc Degradadores irak-4 y síntesis de los mismos
JP2024541933A (ja) 2021-11-02 2024-11-13 ファイザー・インク 抗ｇｄｆ１５抗体を使用してミトコンドリア筋症を処置する方法
WO2023078900A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
JP2024540505A (ja) 2021-11-17 2024-10-31 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル ユニバーサルサルベコウイルスワクチン
JP2025500922A (ja) 2021-12-16 2025-01-15 ヴァレリオ・セラピューティクス 新規のコンジュゲートされた核酸分子及びその使用
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4452257A1 (en) 2021-12-21 2024-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
CN119836296A (zh) 2021-12-30 2025-04-15 新免疫技术有限公司 用il-7蛋白和vegf拮抗剂的组合治疗肿瘤的方法
JP2025503962A (ja) 2022-01-26 2025-02-06 ブリストル－マイヤーズ スクイブ カンパニー 肝細胞がんのための併用療法
WO2023147594A2 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2023150186A1 (en) 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
TWI864587B (zh) 2022-02-14 2024-12-01 美商基利科學股份有限公司 抗病毒吡唑并吡啶酮化合物
US20250152643A1 (en) 2022-02-17 2025-05-15 Regeneron Pharmaceuticals, Inc. Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
AU2023226078A1 (en) 2022-02-25 2024-08-22 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma.
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
KR20230130911A (ko) 2022-03-04 2023-09-12 주식회사 온코인사이트 암 예방 또는 치료를 위한 병용 투여용 약학 조성물
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
JP2025508076A (ja) 2022-03-08 2025-03-21 アレンティス・セラピューティクス・アクチェンゲゼルシャフト Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023174210A1 (en) 2022-03-14 2023-09-21 Laekna Limited Combination treatment for cancer
MX2024011278A (es) 2022-03-15 2024-09-25 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
KR20240161968A (ko) 2022-03-16 2024-11-13 다이이찌 산쿄 가부시키가이샤 다중 특이적 분자와 면역 체크 포인트 저해제의 조합
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2023196988A1 (en) 2022-04-07 2023-10-12 Modernatx, Inc. Methods of use of mrnas encoding il-12
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
US20230326022A1 (en) 2022-04-08 2023-10-12 Bristol-Myers Squibb Company Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
WO2023213764A1 (en) * 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) * 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
KR20250012631A (ko) 2022-05-24 2025-01-24 다이이찌 산쿄 가부시키가이샤 항-cdh6 항체-약물 접합체의 투약
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
CA3258064A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE
WO2024023740A1 (en) 2022-07-27 2024-02-01 Astrazeneca Ab Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
KR20250040960A (ko) 2022-07-28 2025-03-25 아스트라제네카 유케이 리미티드 항체-약물 접합체 및 이중특이적 체크포인트 억제제의 조합
KR20250057801A (ko) 2022-08-02 2025-04-29 리미널 바이오사이언시스 리미티드 아릴-트라이아졸릴 및 관련 gpr84 길항제 및 이의 용도
CN120019047A (zh) 2022-08-02 2025-05-16 里米诺生物科学有限公司 杂芳基甲酰胺和相关gpr84拮抗剂及其用途
KR20250056924A (ko) 2022-08-02 2025-04-28 리미널 바이오사이언시스 리미티드 치환된 피리돈 gpr84 길항제 및 이의 용도
EP4568950A1 (en) 2022-08-08 2025-06-18 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
EP4568963A1 (en) 2022-08-09 2025-06-18 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
EP4568670A1 (en) 2022-08-10 2025-06-18 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
CN119677732A (zh) 2022-08-11 2025-03-21 豪夫迈·罗氏有限公司 双环四氢氮杂䓬衍生物
JP2025526727A (ja) 2022-08-11 2025-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式テトラヒドロチアゼピン誘導体
JP2025526683A (ja) 2022-08-11 2025-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式テトラヒドロチアゼピン誘導体
WO2024052356A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
EP4587040A1 (en) 2022-09-14 2025-07-23 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
US20260015416A1 (en) 2022-09-30 2026-01-15 Alentis Therapeutics Ag Treatment of drug-resistant hepatocellular carcinoma
KR20250089513A (ko) 2022-10-19 2025-06-18 아스텔라스세이야쿠 가부시키가이샤 암 치료에 있어서의 pd-1 시그널 저해제와의 조합에 의한 항cldn4-항cd137 이중특이성 항체의 사용
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
KR20250099224A (ko) 2022-11-01 2025-07-01 하이델베르크 파마 리서치 게엠베하 항-gucy2c 항체 및 이의 용도
US20240190982A1 (en) 2022-11-03 2024-06-13 Incyte Corporation Combination therapies comprising an anti-gitr antibody for treating cancers
WO2024102635A1 (en) 2022-11-07 2024-05-16 Alector Llc Uses of siglec-9 ecd fusion molecules in cancer treatment
KR20250089492A (ko) 2022-11-07 2025-06-18 네오이뮨텍, 인코퍼레이티드 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
EP4623072A2 (en) 2022-11-21 2025-10-01 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
JP2025541738A (ja) 2022-12-01 2025-12-23 ビオンテック・ソシエタス・エウロパエア 抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
KR20250123912A (ko) 2022-12-21 2025-08-18 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 병용 요법
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN116077645A (zh) * 2022-12-28 2023-05-09 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗非小细胞肺癌患者的药物中的用途
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
TW202444754A (zh) 2023-01-30 2024-11-16 英商凱麥博有限公司 抗體
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
EP4676462A1 (en) 2023-03-07 2026-01-14 Photocure ASA Therapy for bladder cancer
EP4680269A1 (en) 2023-03-13 2026-01-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Composition of selected tumor infiltrating lymphocytes and related methods of producing and using the same
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
EP4689658A1 (en) 2023-03-28 2026-02-11 Institut National de la Santé et de la Recherche Médicale Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
KR20250164708A (ko) 2023-03-29 2025-11-25 다이이찌 산쿄 가부시키가이샤 항 cd25 항체 및 항 cd25 항체-약물 콘주게이트
WO2024216028A1 (en) 2023-04-12 2024-10-17 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
WO2024213767A1 (en) 2023-04-14 2024-10-17 Institut National de la Santé et de la Recherche Médicale Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
WO2024228167A1 (en) 2023-05-03 2024-11-07 Iox Therapeutics Inc. Inkt cell modulator liposomal compositions and methods of use
KR20260007566A (ko) 2023-05-04 2026-01-14 노바센타, 인크. 항-cd161 항체 및 이의 사용 방법
AU2024269754A1 (en) * 2023-05-08 2025-10-23 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
CN121057732A (zh) 2023-05-08 2025-12-02 百时美施贵宝公司 经取代的苯基噁唑酮化合物
WO2024231384A1 (en) 2023-05-10 2024-11-14 Institut National de la Santé et de la Recherche Médicale Compositions for treating senescence related disease
TW202509014A (zh) 2023-05-10 2025-03-01 美商纜圖藥品公司 ＧＳＫ３α抑制劑及其使用方法
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
WO2024249540A1 (en) 2023-05-31 2024-12-05 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
AU2024285766A1 (en) 2023-06-07 2026-01-08 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
CN120865251A (zh) 2023-06-23 2025-10-31 凯麦拉医疗公司 Irak降解剂及其用途
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025003193A1 (en) 2023-06-26 2025-01-02 Institut National de la Santé et de la Recherche Médicale Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
WO2025006811A1 (en) 2023-06-27 2025-01-02 Lyell Immunopharma, Inc. Methods for culturing immune cells
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
TW202521540A (zh) 2023-08-04 2025-06-01 法商賽諾菲公司 咪唑并[4,5-d]嗒𠯤化合物及其接合物、其製備、及其治療應用
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
AR133696A1 (es) 2023-09-02 2025-10-22 Bristol Myers Squibb Co Compuestos de fenil oxooxazolil piperidinadiona sustituida
EP4587429A1 (en) 2023-09-13 2025-07-23 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compounds
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025080538A1 (en) 2023-10-09 2025-04-17 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
WO2025080865A1 (en) 2023-10-11 2025-04-17 Turnstone Biologics Corp. Combination of tumor infiltrating lymphocytes (til) and low dose radiation
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
WO2025096638A2 (en) 2023-10-30 2025-05-08 Turnstone Biologics Corp. Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096539A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025132479A1 (en) 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization
WO2025132770A1 (en) 2023-12-22 2025-06-26 Institut National de la Santé et de la Recherche Médicale Affitins for the treatment of cancer
WO2025133391A1 (en) 2023-12-22 2025-06-26 Numab Therapeutics AG Multispecific antibodies having specificity for cd47 and pdl1
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
CN118077649B (zh) * 2024-02-29 2024-09-10 复旦大学附属中山医院 一种免疫检查点抑制剂构建动脉粥样硬化小鼠模型的方法
US20250361297A1 (en) 2024-03-12 2025-11-27 Adaptam Therapeutics, S.L. Anti- siglec-15 binding molecules and methods of use
WO2025210123A1 (en) 2024-04-03 2025-10-09 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating cancers
WO2025210175A1 (en) 2024-04-04 2025-10-09 Centre National De La Recherche Scientifique Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
WO2025213154A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
WO2025219330A1 (en) 2024-04-15 2025-10-23 Institut National de la Santé et de la Recherche Médicale Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
WO2025228998A1 (en) 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma
WO2025232879A1 (en) 2024-05-10 2025-11-13 Cytocares (Shanghai) Inc. Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
WO2025233867A1 (en) 2024-05-10 2025-11-13 Adaptam Therapeutics, S.L. Anti-siglec-9 antibodies and uses thereof
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples
WO2025247829A1 (en) 2024-05-27 2025-12-04 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating prostate cancer
WO2025254987A1 (en) 2024-06-03 2025-12-11 Alector Llc Siglec-9 ecd fusion molecule variants and methods of use thereof
WO2026006604A1 (en) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Feeder cell replacement
WO2026012976A1 (en) 2024-07-08 2026-01-15 Institut National de la Santé et de la Recherche Médicale Use of inhibitor of gasdermind for treatment of rac2 monogenic disorders
WO2026013071A1 (en) 2024-07-09 2026-01-15 Institut National de la Santé et de la Recherche Médicale Setdb1 inhibitor for use in the treatment of uveal melanoma
WO2026015612A1 (en) 2024-07-10 2026-01-15 Regeneron Pharmaceuticals, Inc. Methods of treating smarcb1-deficient cancers

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6808710B1 (en) 1999-08-23 2004-10-26 Genetics Institute, Inc. Downmodulating an immune response with multivalent antibodies to PD-1
US7794710B2 (en) * 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
EP2206517B1 (en) * 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004042072A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
US7329737B2 (en) * 2004-08-03 2008-02-12 Dyax Corp. Antibodies that bind hK-1
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
AU2007339897B2 (en) * 2006-12-27 2013-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of infections and tumors
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
EP4331604B9 (en) * 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2778714C (en) * 2009-11-24 2018-02-27 Medimmune Limited Targeted binding agents against b7-h1
US9115388B2 (en) * 2011-11-01 2015-08-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene signature for the prediction of NF-kappaB activity
ES2808152T3 (es) * 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
US10800846B2 (en) * 2015-02-26 2020-10-13 Merck Patent Gmbh PD-1/PD-L1 inhibitors for the treatment of cancer
US10869924B2 (en) * 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
CA3000386A1 (en) * 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
MY195681A (en) * 2015-12-07 2023-02-03 Merck Patent Gmbh Aqueous Pharmaceutical Formulation Comprising Anti-Pd-L1 Antibody Avelumab
JP2019516748A (ja) * 2016-05-26 2019-06-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ がんを治療するためのｐｄ−１／ｐｄ−ｌ１阻害剤

Also Published As

Publication number Publication date
IL232778B (en) 2020-09-30
EP2785375A1 (en) 2014-10-08
EA036814B1 (ru) 2020-12-23
MX2014006316A (es) 2014-09-04
PT2785375T (pt) 2020-10-29
LT2785375T (lt) 2020-11-10
MX349096B (es) 2017-07-11
ES2808152T3 (es) 2021-02-25
FR20C1068I2 (fr) 2021-11-19
IL276573A (en) 2020-09-30
DK2785375T3 (da) 2020-10-12
KR20170090523A (ko) 2017-08-07
KR20140104982A (ko) 2014-08-29
KR101764096B1 (ko) 2017-08-02
CA2856895A1 (en) 2013-06-06
IL232778A0 (en) 2014-07-31
NL301081I2 (nl) 2021-02-04
ZA201404790B (en) 2021-05-26
LTPA2021001I1 (lt) 2021-01-25
EP2785375B1 (en) 2020-07-22
US10487147B2 (en) 2019-11-26
AR089010A1 (es) 2014-07-23
SMT202000561T1 (it) 2021-01-05
HRP20201595T1 (hr) 2020-12-11
RS61033B1 (sr) 2020-12-31
EA201400625A1 (ru) 2014-11-28
AU2017268603B2 (en) 2019-06-06
US20210054073A1 (en) 2021-02-25
EP3763741A1 (en) 2021-01-13
FR20C1068I1 (nl) 2021-03-05
JP2015500207A (ja) 2015-01-05
SG11201402603WA (en) 2014-06-27
CY2020045I2 (el) 2021-05-05
HUS2000056I1 (hu) 2021-03-01
EA036814B9 (ru) 2021-12-27
WO2013079174A1 (en) 2013-06-06
CA2856895C (en) 2021-10-26
US11884724B2 (en) 2024-01-30
CY1123435T1 (el) 2021-05-05
US9624298B2 (en) 2017-04-18
BR112014012819A2 (pt) 2020-10-20
CN103987405A (zh) 2014-08-13
AU2012344260A1 (en) 2014-07-17
NO2021003I1 (no) 2021-01-19
US10759856B2 (en) 2020-09-01
HUE051954T2 (hu) 2021-03-29
US20170253654A1 (en) 2017-09-07
AU2012344260B2 (en) 2017-09-07
LTC2785375I2 (lt) 2023-04-25
US20140341917A1 (en) 2014-11-20
KR101981873B1 (ko) 2019-05-23
CN103987405B (zh) 2017-03-29
SI2785375T1 (sl) 2020-11-30
US20170253653A1 (en) 2017-09-07
CY2020045I1 (el) 2021-05-05
JP6138813B2 (ja) 2017-05-31
BR112014012819B1 (pt) 2022-08-16
JP2017158553A (ja) 2017-09-14
HK1200736A1 (en) 2015-08-14
AU2017268603A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
FR20C1068I1 (nl)
BR112013031251A2 (nl)
BR112013027245A2 (nl)
BR112013024383A2 (nl)
BR112013023185A2 (nl)
BR112013026905A2 (nl)
BR112013027830A2 (nl)
BR112013026744A2 (nl)
BR112013023927A2 (nl)
BR112013027452A2 (nl)
BR112013024365A2 (nl)
BR112013028733A2 (nl)
BR112013027121A2 (nl)
AP2016009466A0 (nl)
BR112013024588A2 (nl)
BR112013031556A2 (nl)
BR112013026790A2 (nl)
BR112013032366A2 (nl)
BR112013032377A2 (nl)
BR112013032380A2 (nl)
BR112013027836A2 (nl)
BR112013026895A2 (nl)
BR112013027761A2 (nl)
BR112013023266A2 (nl)
BR112013032392A2 (nl)